Ascentage and Innovent’s Olverembatinib Receive NMPA’s Approval for the Treatment of Chronic Myeloid Leukemia
Shots:
- The approval is based on the two P-II studies i.e., HQP1351CC201 & HQP1351CC202 study to evaluate olverembatinib in patients with T315I-mutant CML-CP or CML-AP prior treatment with BCR-ABL1 TKIs
- The results showed that patients treated with olverembatinib were efficacious & well-tolerated while the probability & depth of clinical response will increase with a prolonged treatment period
- Olverembatinib is a third-generation BCR-ABL inhibitor that is developed by Ascentage with support from the National Major New Drug Discovery & Manufacturing program which will co-commercialize in China by both companies. The therapy has received ODD from the US FDA & EMA while FTD from the US FDA
Ref: PR Newswire | Image: Ascentage
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com